



Canada's Largest Cardiac Centre Receives VMS+3.0 Ventripoint Whole Heart Analysis System

Improved cardiac imaging system gaining market adoption with leading medical centers

Toronto, Ontario – The Newswire – November 5, 2020- Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that the Company's proprietary VMS+3.0 whole-heart analysis system has been installed at the Peter Munk Cardiac Center (PMCC) in Toronto, Canada. PMCC is the largest cardiac centre in Canada and resides in the University Hospital Network's (UHN) Toronto General Hospital. This is the 5th hospital in Canada to adopt the new VMS+3.0 for assessing heart function in all four chambers of the heart.

Dr. John Granton, Division Head of Respiriology, UHN, and lead of the Pulmonary Hypertension Program (PHP) stated: "This will help the PHP and the Congenital Heart Disease program manage, and conduct future research in, patients with right heart failure."

"Just as it is PMCC's mission to use the best equipment to optimize patient care, it has always been the Company's mission to create "best-in-breed" equipment to assist clinicians and medical personnel in a myriad of clinical settings to accurately assess heart function. We feel incredibly privileged to have this world-leading hospital adopt our system," stated Dr. George Adams, Executive-Chairman of Ventripoint.

The Company has installed three VMS+3.0 whole heart analysis systems in three top-rated hospitals in the last 5 weeks. The Company has delivered 10 VMS+3.0 systems to date and expects to install units in additional leading cardiac centres before the end of the year.

The Company estimates that 40,000 VMS+3.0 units would be required based on standard-of-care guidelines to effectively diagnose, monitor and manage the health of patients with congenital heart disease, pulmonary hypertension and those suffering cardiotoxicity due to chemotherapy.

About the Peter Munk Cardiac Centre

Peter Munk Cardiac Centre is part of the University Health Network (UHN) and is located at the Toronto General Hospital in Toronto, Ontario, Canada. This cardiac centre is a world leader in the diagnosis, care and treatment of cardiovascular disease.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Mr. Jonathan Robinson
Email: JRobinson@oakhillfinancial.ca
Phone: (416) 669-1001

Or

Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-

looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.